On September 29, Marksans Pharma Limited received approval from the FDA for its ANDA217264 to market Esomeprazole Magnesium Delayed-Release Capsules, 20 mg. This clearance is expected to broaden the brand’s market presence in the acid-reduction therapeutic class, leveraging an established generic window to drive additional revenue streams.